U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hype
Go back to U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hype| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 55.53 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.53 | 52 Week High | $77.12 | |||
| Open | $55.53 | 52 Week Low | $49.03 | |||
| Day High | $55.53 | P/E | 36.06 | |||
| Day Low | $55.53 | EPS | $1.54 | |||
| Volume | 1,538 | |||||
